Third Rock launches Tango Therapeutics with $55M Series A to develop novel medicines designed to target cancer vulnerabilities
Read More
Third Rock Launches Goldfinch Bio with $55M Series A to Develop Precision Therapies for Kidney Disease
Read More
Congratulations to Voyager Therapeutics on being named one of The Boston Globe's 2016 Top Places to Work
Read More
Third Rock launches Magenta Therapeutics with $48.5M to Apply New Stem Cell Science to Reboot the Immune System
Read More
Eleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company
Read More
Third Rock launches Relay Therapeutics with $57M to build the world’s first dedicated drug discovery platform centered on protein motion
Read More
Andrew Stricos, who has Huntington’s disease, and his wife tell their story at a luncheon hosted by Third Rock
Watch the VideoTransforming Healthcare
44
Portfolio Companies
With More Than $1.9 Billion
Under Management
45
Clinical Studies
Underway Within Our Portfolio
60
Diseases
Being Targeted By
Our Companies
10
of thousands
Patients Impacted
By Portfolio Company Products
and Clinical Trials